Skip to main content
Erschienen in: Journal of Endocrinological Investigation 8/2015

01.08.2015 | Original Article

Analysis of RAS mutation and PAX8/PPARγ rearrangements in follicular-derived thyroid neoplasms in a Korean population: frequency and ultrasound findings

verfasst von: S. H. Jeong, H. S. Hong, J. J. Kwak, E. H. Lee

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 8/2015

Einloggen, um Zugang zu erhalten

Abstract

Objective

To investigate the frequency and ultrasonography (US) findings of RAS mutations and PAX8/PPARγ rearrangements between follicular thyroid adenomas (FTAs) and follicular thyroid carcinomas (FTCs) in a Korean population.

Methods

RAS mutations and PAX8/PPARγ rearrangements in 56 FTAs and 35 FTCs were analyzed. We also analyzed the US findings of FTCs and FTAs.

Results

16 nodules of 35 FTCs (45.7 %) and 19 nodules of 56 FTAs (33.9 %) harbored RAS mutations. Three FTCs and three FTAs showed two point mutations simultaneously. K-RAS codon 12–13 (n = 6, 31.6 %), N-RAS codon 61 (n = 5, 26.3 %), H-RAS codon 61 (n = 4, 21.1 %), K-RAS codon 61 (n = 3, 15.8 %), and N-RAS codon 12–13 (n = 1, 5.3 %) were found in FTCs, and N-RAS codon 61 (n = 10, 45 %), K-RAS codon 12–13 (n = 5, 22.7 %), H-RAS codon 61 (n = 5, 22.7 %), K-RAS codon 61 (n = 1, 4.5 %), and N-RAS codon 12–13 (n = 1, 4.5 %) were observed in FTAs. 4 of 56 (7.1 %) FTAs and 1 of 35 (2.9 %) FTCs represented PAX8/PPARγ rearrangements, respectively (P = 0.645). The absence of a hypoechoic rim (P = 0.021) and presence of calcifications (P = 0.049) were significantly associated with FTCs compared with FTAs.

Conclusions

RAS mutation frequency targeting the Korean population showed a 45.7 % in FTCs and 35.7 % in FTAs, and PAX8/PPARγ rearrangements were more frequently showed in FTAs. K-RAS codon 12–13 was the most common RAS mutation in FTCs, whereas N-RAS codon 61 was more frequent in FTAs. The presence of calcifications and absence of a hypoechoic rim showed more frequently in FTCs.
Literatur
1.
Zurück zum Zitat Grebe SK, Hay ID (1995) Follicular thyroid cancer. Endocrinol Metab Clin North Am 24(4):761–801PubMed Grebe SK, Hay ID (1995) Follicular thyroid cancer. Endocrinol Metab Clin North Am 24(4):761–801PubMed
2.
3.
Zurück zum Zitat D’Avanzo A, Treseler P, Ituarte PH et al (2004) Follicular thyroid carcinoma: histology and prognosis. Cancer 100(6):1123–1129PubMedCrossRef D’Avanzo A, Treseler P, Ituarte PH et al (2004) Follicular thyroid carcinoma: histology and prognosis. Cancer 100(6):1123–1129PubMedCrossRef
4.
Zurück zum Zitat Nikiforova MN, Lynch RA, Biddinger PW et al (2003) RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 88(5):2318–2326PubMedCrossRef Nikiforova MN, Lynch RA, Biddinger PW et al (2003) RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 88(5):2318–2326PubMedCrossRef
5.
Zurück zum Zitat Lin JD, Chao TC (2006) Follicular thyroid carcinoma: from diagnosis to treatment. Endocr J 53(4):441–448PubMedCrossRef Lin JD, Chao TC (2006) Follicular thyroid carcinoma: from diagnosis to treatment. Endocr J 53(4):441–448PubMedCrossRef
7.
Zurück zum Zitat Banito A, Pinto AE, Espadinha C, Marques AR, Leite V (2007) Aneuploidy and RAS mutations are mutually exclusive events in the development of well-differentiated thyroid follicular tumours. Clin Endocrinol (Oxf) 67(5):706–711CrossRef Banito A, Pinto AE, Espadinha C, Marques AR, Leite V (2007) Aneuploidy and RAS mutations are mutually exclusive events in the development of well-differentiated thyroid follicular tumours. Clin Endocrinol (Oxf) 67(5):706–711CrossRef
8.
Zurück zum Zitat Namba H, Rubin SA, Fagin JA (1990) Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol 4(10):1474–1479PubMedCrossRef Namba H, Rubin SA, Fagin JA (1990) Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol 4(10):1474–1479PubMedCrossRef
9.
Zurück zum Zitat Suarez HG, du Villard JA, Severino M et al (1990) Presence of mutations in all three ras genes in human thyroid tumors. Oncogene 5(4):565–570PubMed Suarez HG, du Villard JA, Severino M et al (1990) Presence of mutations in all three ras genes in human thyroid tumors. Oncogene 5(4):565–570PubMed
10.
Zurück zum Zitat Esapa CT, Johnson SJ, Kendall-Taylor P, Lennard TW, Harris PE (1999) Prevalence of ras mutations in thyroid neoplasia. Clin Endocrinol (Oxf) 50(4):529–535CrossRef Esapa CT, Johnson SJ, Kendall-Taylor P, Lennard TW, Harris PE (1999) Prevalence of ras mutations in thyroid neoplasia. Clin Endocrinol (Oxf) 50(4):529–535CrossRef
11.
Zurück zum Zitat Marques AR, Espadinha C, Catarino AL et al (2002) Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 87(8):3947–3952PubMed Marques AR, Espadinha C, Catarino AL et al (2002) Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 87(8):3947–3952PubMed
12.
Zurück zum Zitat Marques AR, Espadinha C, Frias MJ et al (2004) Underexpression of peroxisome proliferator-activated receptor (PPAR)gamma in PAX8/PPARgamma-negative thyroid tumours. Br J Cancer 91(4):732–738PubMedCentralPubMed Marques AR, Espadinha C, Frias MJ et al (2004) Underexpression of peroxisome proliferator-activated receptor (PPAR)gamma in PAX8/PPARgamma-negative thyroid tumours. Br J Cancer 91(4):732–738PubMedCentralPubMed
13.
15.
Zurück zum Zitat Forbes SA, Bindal N, Bamford S et al (2011) COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Res 39:D945–D950PubMedCentralPubMedCrossRef Forbes SA, Bindal N, Bamford S et al (2011) COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Res 39:D945–D950PubMedCentralPubMedCrossRef
16.
Zurück zum Zitat Park KY, Koh JM, Kim YI et al (1998) Prevalences of Gs alpha, ras, p53 mutations and ret/PTC rearrangement in differentiated thyroid tumours in a Korean population. Clin Endocrinol (Oxf) 49(3):317–323CrossRef Park KY, Koh JM, Kim YI et al (1998) Prevalences of Gs alpha, ras, p53 mutations and ret/PTC rearrangement in differentiated thyroid tumours in a Korean population. Clin Endocrinol (Oxf) 49(3):317–323CrossRef
17.
Zurück zum Zitat Kim HJ, Jang HW, Sohn SY et al (2012) Frequency of RAS mutations and PAX8/PPARgamma rearrangement in follicular thyroid tumors in Korea. Endocrinol Metab 27(1):45–53CrossRef Kim HJ, Jang HW, Sohn SY et al (2012) Frequency of RAS mutations and PAX8/PPARgamma rearrangement in follicular thyroid tumors in Korea. Endocrinol Metab 27(1):45–53CrossRef
18.
Zurück zum Zitat Garcia-Rostan G, Zhao H, Camp RL et al (2003) Ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol 21(17):3226–3235PubMedCrossRef Garcia-Rostan G, Zhao H, Camp RL et al (2003) Ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol 21(17):3226–3235PubMedCrossRef
19.
Zurück zum Zitat Fukahori M, Yoshida A, Hayashi H et al (2012) The associations between RAS mutations and clinical characteristics in follicular thyroid tumors: new insights from a single center and a large patient cohort. Thyroid 22(7):683–689PubMedCrossRef Fukahori M, Yoshida A, Hayashi H et al (2012) The associations between RAS mutations and clinical characteristics in follicular thyroid tumors: new insights from a single center and a large patient cohort. Thyroid 22(7):683–689PubMedCrossRef
20.
Zurück zum Zitat Vasko V, Ferrand M, Di Cristofaro J, Carayon P, Henry JF, de Micco C (2003) Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J Clin Endocrinol Metab 88(6):2745–2752PubMedCrossRef Vasko V, Ferrand M, Di Cristofaro J, Carayon P, Henry JF, de Micco C (2003) Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J Clin Endocrinol Metab 88(6):2745–2752PubMedCrossRef
21.
Zurück zum Zitat Yoshimoto K, Iwahana H, Fukuda A et al (1992) Ras mutations in endocrine tumors: mutation detection by polymerase chain reaction-single strand conformation polymorphism. Jpn J Cancer Res 83(10):1057–1062PubMedCrossRef Yoshimoto K, Iwahana H, Fukuda A et al (1992) Ras mutations in endocrine tumors: mutation detection by polymerase chain reaction-single strand conformation polymorphism. Jpn J Cancer Res 83(10):1057–1062PubMedCrossRef
22.
Zurück zum Zitat Liu RT, Hou CY, You HL et al (2004) Selective occurrence of ras mutations in benign and malignant thyroid follicular neoplasms in Taiwan. Thyroid 14(8):616–621PubMedCrossRef Liu RT, Hou CY, You HL et al (2004) Selective occurrence of ras mutations in benign and malignant thyroid follicular neoplasms in Taiwan. Thyroid 14(8):616–621PubMedCrossRef
23.
Zurück zum Zitat Manenti G, Pilotti S, Re FC, Della Porta G, Pierotti MA (1994) Selective activation of ras oncogenes in follicular and undifferentiated thyroid carcinomas. Eur J Cancer 30A(7):987–993PubMedCrossRef Manenti G, Pilotti S, Re FC, Della Porta G, Pierotti MA (1994) Selective activation of ras oncogenes in follicular and undifferentiated thyroid carcinomas. Eur J Cancer 30A(7):987–993PubMedCrossRef
24.
Zurück zum Zitat McIver B, Grebe SK, Eberhardt NL (2004) The PAX8/PPAR gamma fusion oncogene as a potential therapeutic target in follicular thyroid carcinoma. Curr Drug Targets Immune Endocr Metabol Disord 4(3):221–234PubMedCrossRef McIver B, Grebe SK, Eberhardt NL (2004) The PAX8/PPAR gamma fusion oncogene as a potential therapeutic target in follicular thyroid carcinoma. Curr Drug Targets Immune Endocr Metabol Disord 4(3):221–234PubMedCrossRef
Metadaten
Titel
Analysis of RAS mutation and PAX8/PPARγ rearrangements in follicular-derived thyroid neoplasms in a Korean population: frequency and ultrasound findings
verfasst von
S. H. Jeong
H. S. Hong
J. J. Kwak
E. H. Lee
Publikationsdatum
01.08.2015
Verlag
Springer International Publishing
Erschienen in
Journal of Endocrinological Investigation / Ausgabe 8/2015
Elektronische ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-015-0311-x

Weitere Artikel der Ausgabe 8/2015

Journal of Endocrinological Investigation 8/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.